Cara Therapeutics Inc. said Dean Slagel submitted his resignation as director with effect from March 7.
Slagel was the longest tenured director of the company, having joined the board in 2005, the biopharma said in an SEC filing.
Stamford, Conn.-based Cara Therapeutics is a clinical-stage biopharmaceutical company which focuses on developing and marketing pain management therapies.
